Expansion of US TrakCel team to match ongoing growth of cell and gene therapy customer base
Cardiff, UK, July 2nd, 2019 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, announces today the appointment of Maryellen Papelian as senior director of customer delivery.
“TrakCel’s software orchestration platforms are now an integral component throughout much of the international clinical development of the cell and gene therapy industry. As the sector continues to expand, and we work with a greater number of companies, it is critical that we in turn expand capabilities to support existing clients in key international regions. This includes further expansion of our US customer management,” said Ravi Nalliah, CEO, TrakCel. “We selected Maryellen Papelian as a specialist in the implementation of supply chain orchestration platforms at scale. She will provide the integral link between the specific requirements of the client and TrakCel’s software to ensure our individually tailored packages are adjusted on an ongoing basis to the evolving needs of the client.”
Maryellen brings to TrakCel over 20 years experience in large-scale IT roll-out implementations focusing on re-engineering business processes. In the last seven years, Maryellen has successfully set the IT infrastructure, and developed business processes for the successful rollout of solutions supporting a number of clinical to commercial product launches. These solutions range from legal, finance, quality, regulatory, clinical, HR, manufacturing, and supply chain. She additionally acquired extensive biotech experience as the director of enterprise applications at the genome editing company Editas Medicine, the gene therapy firm bluebird bio, the rare disease company Synageva, and Haemonetics, which provides blood management solutions. As a result, Maryellen provides TrakCel additional industry insight of project deliveries from both a client and supplier viewpoint.
Maryellen is TrakCel’s latest US senior appointment as the company expands its US management team. This is to ensure TrakCel continues to meet existing business requirements as the number of clients operating in the US continues to grow. This will enable TrakCel to continue to provide senior and highly qualified locally based support to cell and gene therapy client operations in both the EU and US.
“The cell and gene therapy industry continues to grow and evolve. This results in more complex supply chains with broader therapeutic indications and wider geographical clinical operations. These challenges mean the demand for implementation software will continue to increase,” said Maryellen Papelian, senior director of customer delivery, TrakCel. “I have been part of the selection and implementation of a variety of supply chain systems in my recent career. As a result, from that experience, I wanted to apply my technical, commercial and industry experience to TrakCel’s ethos and technical solutions. I feel this is the best option for me to contribute to life changing personalized medicines reaching the market and benefiting patients.”
TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.
TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.